please help asap

Interpreting Acquisition Footnote with In-Process Research and DevelopmentOn October 3, 2017, Gilead Sciences, Inc. (Gilead) acquired 100% of the outstanding common stock of Kite Pharma, Inc. (Kite). According to Gilead's December 31, 2017 Securities and Exchange Com-mission Form 10-K, "[t]he acquisition of Kite was accounted for as a business combination using the acquisition method of accounting." The following excerpt is from Note 5 (i.e., Acquisitions) of Gilead's 2017 10-K:

The following table summarizes the preliminary acquisition date fair values of assets acquired and liabilities assumed, and the consideration transferred (in millions): Cash and cash equivalents .............................................. $ 652 Identifiable intangible assets Indefinite-lived intangible assetslPFl&D ................................. 8,950 Outlicense acquired .................................................. 91 Deferred income taxes .................................................. (1,606) Other assets acquired (liabilities assumed), net ............................... 81 Total identifiable net assets ............................................. 8,168 Goodwill ............................................................. 2,987 Total consideration transferred .......................................... $11 .155